Akeso

Akeso's Ivonescimab Hits 70.1% Pathological Response in NSCLC Trial

Image
Akeso's Ivonescimab Hits 70.1% Pathological Response in NSCLC Trial

Hong Kong – November 06, 2026 -- Akeso's PD-1/VEGF bispecific antibody ivonescimab combined with chemotherapy produced a 70.1% major pathological response (MPR) rate and a 50.7% pathological complete response (pCR) rate in resectable non-small cell lung cancer (NSCLC), according to Phase II results published in Nature Medicine.

Chemotherapy combination delivers 70.1% MPR and 100% R0 resection

The trial tested perioperative ivonescimab as monotherapy or with chemotherapy. Patients received neoadjuvant treatment, then surgery, then adjuvant ivonescimab. Among patients who underwent surgery in the combination cohort, 68.7% had residual viable tumor of 5% or less.

Akeso's Ivonescimab Wins China Priority Review in Biliary Cancer

HONG KONG – – November 05, 2026 -- China's National Medical Products Administration (NMPA) has granted Priority Review to Akeso's ivonescimab plus chemotherapy for first-line locally advanced or metastatic biliary tract cancer (BTC), a designation expected to accelerate the subsequent regulatory review in China.

HARMONi-GI1 Phase III trial beats durvalumab regimen on overall survival

In the randomized, double-blind, multicenter HARMONi-GI1 study (AK112-309), ivonescimab plus chemotherapy was compared with durvalumab plus chemotherapy, the current global first-line standard in BTC. A prespecified interim analysis reviewed by the Independent Data Monitoring Committee showed the trial met its primary endpoint of overall survival (OS). The improvement over the control arm was statistically significant and clinically meaningful. The study also met all key secondary endpoints, including progression-free survival and objective response rate.

Akeso Enrolls First Patient in Global Phase III Gastric Cancer Trial

Hong Kong – September 28, 2026 -- Akeso, Inc. (9926.HK) has enrolled the first patient in COMPASSION-37, a global Phase III head-to-head trial testing its bispecific antibody cadonilimab against nivolumab as first-line treatment for HER2-negative advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.

Trial pits cadonilimab plus chemotherapy against nivolumab-based standard of care

The multicenter study compares cadonilimab combined with chemotherapy to chemotherapy with or without nivolumab in previously untreated, unresectable or metastatic G/GEJ patients. It is co-led by Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, and Professors Jiafu Ji and Lin Shen of Peking University Cancer Hospital. Janjigian, Möhler and Shen were investigators on the earlier CheckMate 649 trial, which established nivolumab plus chemotherapy as a global first-line standard.

Akeso's Ivonescimab Wins ESMO Late-Breaking Slot for Biliary Cancer Data

Hong Kong – September 22, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Phase III biliary tract cancer trial secures Presidential Symposium slot

Overall survival results from the Phase III HARMONi-GI1 trial, comparing ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for advanced biliary tract cancer, will be delivered as a late-breaking oral presentation (LBA8) on October 25 at 16:30-18:15 in Madrid. The presentation will be given by Jian Zhou of Shanghai during Presidential Symposium II.